BeOne Reports Survival Data for Cancer Drug Regimen

A new Phase 3 study shows improved survival outcomes for patients with advanced gastroesophageal adenocarcinoma.

Updated on Oct. 23, 2026 in Cancer

Clinical laboratory workstation featuring clear glass beakers and a microscope, reflecting medical research and drug trial data. — BeOne Medicines reported that a drug combination of Tevimbra and Ziihera improved median survival rates to 27 months in clinical trials. AI Illustration. Upload story photo >

Live Poll

Do you trust that new pharmaceutical clinical study results accurately predict long-term patient outcomes?

BeOne Medicines announced that a combination of Tevimbra and Ziihera with chemotherapy improved survival rates for patients with locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma. The regimen achieved a median overall survival of 27 months in the clinical trial.

Why it matters

These results provide critical efficacy data for the treatment, which received U.S. regulatory approval earlier this year. The findings help doctors compare the benefits of adding Tevimbra to standard chemotherapy and Ziihera protocols for patients regardless of PD-L1 status.

Patients receiving the Tevimbra and Ziihera combination reached a three-year survival rate of nearly 40%. The median overall survival reached 27 months, outperforming the 22.9-month median survival seen in the Ziihera-only chemotherapy arm.

The players

BeOne Medicines

This pharmaceutical company specializes in developing targeted therapies for oncology patients.

The details

The study evaluated the effectiveness of these drug combinations against a control regimen of chemotherapy and trastuzumab. Researchers analyzed outcomes for all participants, regardless of their PD-L1 status, to determine the broader utility of the therapy in treating this aggressive form of cancer.

August 2026: The treatment received U.S. regulatory approval.
October 23, 2026: BeOne Medicines published the Phase 3 trial report.

Health Landscape

This development marks a significant update to the standard-of-care protocol for gastroesophageal adenocarcinoma. By integrating new immunotherapy agents, the findings provide a more effective clinical pathway that improves upon previous benchmarks for metastatic cancer treatment.

Patients diagnosed with advanced gastroesophageal adenocarcinoma may now have access to a more effective, FDA-approved treatment regimen that has been clinically shown to extend survival times. Healthcare providers can use these updated findings to better tailor treatment plans based on the proven efficacy of the Tevimbra and Ziihera combination.

The takeaway

These findings underscore the importance of ongoing clinical evaluation in refining combination therapies for metastatic cancers. Patients and their care teams should discuss these updated survival metrics to determine if this specific drug regimen aligns with their current treatment goals.